Biocon opens first US manufacturing facility in Cranbury, New Jersey

IMT News Desk
IMT News Desk
· 2 min read

The Cranbury facility represents a strategic advancement for the company’s US operations

Biocon announced the inauguration of its first US manufacturing facility in Cranbury, New Jersey, by its wholly owned subsidiary, Biocon Generics Inc (BGI).

Governor of New Jersey, Phil Murphy, was the guest of honour at the inauguration. Biocon’s Chairperson, Kiran Mazumdar-Shaw, and a distinguished gathering of dignitaries, customers, partners, and industry leaders were in attendance.  

The Cranbury facility represents a strategic advancement for the company’s US operations, enabling faster access to essential therapies, enhanced supply reliability, and a stronger connection with partners and healthcare providers, ultimately benefitting patients across the US.

Kiran Mazumdar-Shaw, Chairperson, Biocon Group, said, “Biocon’s first US FDA-approved The formulations facility in New Jersey marks a new chapter in our journey of global expansion. More than a milestone, it is a reaffirmation of our purpose to serve patients wherever they are. Governor Phil Murphy’s presence at the inauguration highlights the importance of Biocon’s role in fostering innovation, creating job opportunities, and strengthening the US healthcare ecosystem. This facility reflects our long-term commitment to deeper engagement with healthcare providers, innovators, and communities to build a healthier and equitable future.”

Siddharth Mittal, CEO and Managing Director, Biocon, commented, “We were deeply honoured to have Governor Phil Murphy and our Chairperson, Kiran Mazumdar-Shaw, join us in marking this milestone of the Biocon Group’s first manufacturing facility in the US. This strategic investment brings us closer to patients, healthcare providers, and partners in this important market. The proximity allows us to deliver our vertically integrated, high-quality medicines more efficiently to patients across the United States and other markets, ensuring supply chain resilience and enabling us to advance our mission of expanding access to affordable therapies worldwide.”

“We are grateful that Biocon has decided to open its first US manufacturing facility in the
Garden State,” said Governor Murphy. “For years, Biocon has provided high-quality medicines
and treatments to millions of patients across the globe. This state-of-the-art facility marks a
significant moment in Biocon’s global expansion and reinforces New Jersey’s reputation as the
medicine chest to the world.”

Read Next

Agenus announces closing of $141 M strategic collaboration with Zydus Lifesciences
Global News
January 20, 2026

Agenus announces closing of $141 M strategic collaboration with Zydus Lifesciences

To advance BOT+BAL and strengthen US manufacturing readiness Agenus, a leader in immuno-oncology innovation, announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The agreement is designed to accelerate global development and potential commercialisation of Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination programme. The collaboration provides Agenus with strategic capital and […]
Article by: IMT News Desk
Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia
Global News
January 16, 2026

Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia

Approval marks Venus Remedies’ first anti-infective marketing authorisation in Indonesia and enables the country’s first generic entry for this critical antibiotic combination Venus Remedies has secured the marketing authorisation from the Indonesian regulatory authority for its combination antibiotic, Ceftazidime + Avibactam. This approval represents Venus Remedies’ first marketing authorization in the anti-infective segment in Indonesia […]
Article by: IMT News Desk
Wegovy pill approved in the US for weight management
Global News
December 26, 2025

Wegovy pill approved in the US for weight management

Novo Nordisk expects to launch the Wegovy pill in the US in early January 2026 Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse […]
Article by: IMT News Desk
Samsung Biologics America in agreement to acquire 100 per cent of Human Genome Sciences from GSK
Global News
December 24, 2025

Samsung Biologics America in agreement to acquire 100 per cent of Human Genome Sciences from GSK

Under the terms of the agreement, with closing anticipated toward the end of Q1 of 2026, Samsung Biologics will acquire the Rockville assets for $280 million Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced that its wholly owned US subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100 […]
Article by: IMT News Desk